About Michelle Anastasi

1 POSTS 0 COMMENTS

Michelle Anastasi is Director, Quality Management & Compliance, US, at PharmaLex, where she serves as the international service lead for GxP Quality Management Systems including eQMS / eDMS. Michelle has more than 20 years of industry experience in quality management and GMP.

Going Beyond the Guidance: Getting Business Benefit from Change Management

Michelle Anastasi - April 20, 2023

LATEST NEWS

Trastuzumab Deruxtecan Is an Effective Option for Difficult-to-treat HER2-expressing Solid Tumors

Editorial Team - June 5, 2023

Mirvetuximab Soravtansine Improves Survival in Women With Recurrent Ovarian Cancer

Editorial Team - June 4, 2023

Study Shows Nivolumab Reduces Risk of Disease Progression in Advanced, Untreated Hodgkin Lymphoma

Editorial Team - June 4, 2023

Adjuvant Osimertinib Significantly Improves Survival in Patients With Resected EGFR-Mutated NSCLC

Editorial Team - June 4, 2023

Vorasidenib Significantly Improves Progression-free Survival in Grade 2 Glioma with IDH Mutation

Editorial Team - June 4, 2023

Press Releases | Cancer

OncoLens Virtual Tumor Board platform connects the best minds,... June 2, 2023
OncoLens and the Sarcoma Alliance for Research Through Collaboration (SARC) are thrilled to launch a nationwide virtual sarcoma tumor board program as part of a strategic partnership to enhance...(PRWeb June 02, 2023)Read the full story at https://www.prweb.com/releases/2023/6/prweb19369925.htm
Equify Health Receives $1 Million Grant to Launch Transformative... May 31, 2023
Workshop Will Train Medical Providers to Deliver Inclusive Care to Minority Patients(PRWeb May 31, 2023)Read the full story at https://www.prweb.com/releases/2023/5/prweb19355613.htm
University Cancer & Blood Center recognizes importance of clinical... May 25, 2023
UCBC offers access to latest, greatest cancer treatment therapies(PRWeb May 25, 2023)Read the full story at https://www.prweb.com/releases/university_cancer_blood_center_recognizes_importance_of_clinical_trials_during_national_cancer_research_month/prweb19358186.htm

Michelle Anastasi

Going Beyond the Guidance: Getting Business Benefit from Change Management

LATEST NEWS

Trastuzumab Deruxtecan Is an Effective Option for Difficult-to-treat HER2-expressing Solid Tumors

Mirvetuximab Soravtansine Improves Survival in Women With Recurrent Ovarian Cancer

Study Shows Nivolumab Reduces Risk of Disease Progression in Advanced, Untreated Hodgkin Lymphoma

Adjuvant Osimertinib Significantly Improves Survival in Patients With Resected EGFR-Mutated NSCLC

Vorasidenib Significantly Improves Progression-free Survival in Grade 2 Glioma with IDH Mutation

Trastuzumab Deruxtecan Is an Effective Option for Difficult-to-treat HER2-expressing Solid Tumors

Mirvetuximab Soravtansine Improves Survival in Women With Recurrent Ovarian Cancer

Study Shows Nivolumab Reduces Risk of Disease Progression in Advanced, Untreated Hodgkin Lymphoma

Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics

How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall?

Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’...